Clinical Trial

IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer

Name: IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer — clinical trial record (NCT07674615)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

To observe the efficacy and safety of IMMU-132 in patients with advanced or recurrent ovarian cancer with high TROP-2 expression in tumor tissue, who have failed standard therapy or are unable to receive standard treatment.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-06-24.

Trial Details

NCT Number	NCT07674615
Lead Sponsor	Shanghai Gynecologic Oncology Group
Conditions	Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary, Primary Peritoneal Carcinoma
Enrollment	19 participants
Start Date	2026-07-01
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-30